ATX-MS-1467

February 22, 2017February 22, 2017

Apitope’s ATX-MS-1468 Therapy Decreases Brain Lesions in Relapsing MS Patients

News

Treatment with Apitope’s lead agent, ATX-MS-1467, decreased brain lesions in patients with relapsing multiple sclerosis (MS) in a now-completed Phase 2a clinical trial. ATX-MS-1467 is a potential ... Read more

October 19, 2016October 19, 2016

Apitope Regains Full Rights to Potential MS Therapy, ATX-MS-1467

News

Apitope and Merck KGaA announced that they have entered into an exclusive agreement regarding ATX-MS-1467, a potential disease-modifying therapy for multiple sclerosis (MS). Under its terms, Apitope will regain full global ... Read more

August 10, 2015August 10, 2015

Apitope Completes Enrollment for Phase IIa Trial for Relapsing Multiple Sclerosis

Multiple Sclerosis News, News

Apitope, a biocompany devoted to drug discovery and development for autoimmune diseases, announced that its partner Merck Serono has concluded the recruitment of participants for its Phase ... Read more

Pin It on Pinterest